SEARCH

SEARCH BY CITATION

References

  • 1
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958965.
  • 2
    Fried MW, Shiffman ML, Reddy R, Smith C, Marinos G, Gonçales FL, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975982.
  • 3
    Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346355.
  • 4
    Zeuzem S, Hultcrantz R, Bourlier M, Goesse T, Marcellin P, Sánchez-Tapias J, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotype 2 or 3. J Hepatol 2004; 40: 993999.
  • 5
    Dalgard O, Bjoro K, Hellum KB, Myrvang B, Ritland S, Skaug K, et al. Treatment with pegylated interferon and ribavirin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. HEPATOLOGY 2004; 41: 12601265.
  • 6
    Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005; 352: 26092617.
  • 7
    National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002. HEPATOLOGY 2002; 36: S3S20.
  • 8
    Alberti A, Benvegnú L. Management of hepatitis C. J Hepatol 2003; 38: S104S118.
  • 9
    Strader DB, Wright T, Thomas TL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. HEPATOLOGY 2004; 39: 11471171.
  • 10
    Zeuzem S, Esteban-Mur R, Buti M, Ferenci P, Sperl J, Horsmans Y, et al. Efficacy of 24 weeks of treatment with peginterferon alfa-2b 1,5 μg/kg/week plus ribavirin 800–1.400 mg/day (p/r) in patients infected with chronic hepatitis C with genotype 1 with low viral load (lgvl) [Abstract]. Gastroenterology 2005; 128( Suppl 1): A716.
  • 11
    Sánchez-Tapias JM, Diago M, Escartín P, Enríquez J, Moreno R, Romero-Gómez M, et al. Longer treatment duration with peginterferon alfa-2a (40 Kd) (Pegasys) and ribavirin (Copegus) in naïve patients with chronic hepatitis C and detectable HCV-RNA by week 4 of therapy: final results of the randomized, multicenter TERAVIC study [Abstract]. HEPATOLOGY 2004; 40( Suppl 1): 218A.
  • 12
    Ferenci P. Predictors of response to therapy for chronic hepatitis C. Semin Liver Dis 2004; 24( Suppl 2): 2531.
  • 13
    Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med 2004; 140: 370381.
  • 14
    López-Labrador FX, Ampurdanés S, Forns X, Castells A, Sáiz JC, Costa J, et al. Hepatitis C virus (HCV) genotypes in Spanish patients with HCV infection: relationship between HCV genotype 1b, cirrhosis and hepatocellular carcinoma. J Hepatol 1997; 27: 959965.
  • 15
    Forns X, Martínez-Bauer E, Felíu A, García-Retortillo M, Martín M, Gay E, et al. Nosocomial transmission of HCV in the liver unit of a tertiary care center. HEPATOLOGY 2005; 41: 115122.
  • 16
    Scheuer PJ. Classification of chronic hepatitis; a need for reassessment. J Hepatol 1991; 13: 372374.
  • 17
    Forns X, Ampurdanés S, Llovet JM, Aponte J, Quintó Ll, Martínez-Bauer E, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. HEPATOLOGY 2002; 36: 986992.
  • 18
    Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albretch J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. HEPATOLOGY 2003; 38: 645652.
  • 19
    Lefrère JJ, Roudot-Thoroval F, Lunel F, Alain S, Chaix ML, Dussaix E, et al. Expertise of French laboratories in detection, genotyping, and quantification of hepatitis C virus RNA in serum. J Clin Microbiol 2004; 42: 20272030.
  • 20
    Davis GL, Lau JYN, Urdea MS, Neuwald P, Wilber JC, Lindsay K, et al. Quantitative detection of hepatitis C virus (HCV) RNA by a solid-phase signal amplification method: definition of optimal conditions for specimen collection and clinical application in interferon-treated patients. HEPATOLOGY 1994; 19: 13371341.
  • 21
    Lee SS, Heathcote EJ, Reddy KR, Zeuzem S, Fried MW, Wright TL, et al. Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40 KD). J Hepatol 2002; 37; 500506.
  • 22
    Berg T, Sarrazin C, Herrmann E, Hinrichsen H, Gerlach T, Zachoval R, et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. HEPATOLOGY 2003; 37: 600609.
  • 23
    Romero-Gómez M, Del Mar Viloria M, Andrade RJ, Salmerón J, Diago M, Fernández-Rodríguez CM, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128: 636641.
  • 24
    Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1996; 352: 14261432.
  • 25
    Braitman LE, Davidoff F. Predicting clinical states in individual patients. Ann Intern Med 1996; 125: 406412.
  • 26
    Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. HEPATOLOGY 1981; 1: 431435.
  • 27
    The French Metavir Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. HEPATOLOGY 1994; 20: 1520.
  • 28
    Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696699.
  • 29
    Regev V, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97: 26142618.
    Direct Link:
  • 30
    Rousselet MC, Michalak S, Dupré F, Croué A, Bedossa P, Saint-André JP, et al. Sources of variability in histological scoring of chronic viral hepatitis. HEPATOLOGY 2005; 41: 257264.
  • 31
    Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with chronic hepatitis C virus infection: a prospective study. Lancet 2001; 357: 10691075.
  • 32
    Wai CT, Greerson JK, Fontana RJ, Kalbfleish JD, Marrero JA, Conjeevaram HS, et al. A simple non-invasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. HEPATOLOGY 2003; 38: 518526.
  • 33
    Castéra L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343350.
  • 34
    Ziol M, Handra-Luca A, Kettaneh A, Christidis C, Mal F, Kazemi F, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. HEPATOLOGY 2005; 41: 4855.
  • 35
    Gavier B, Martínez-González MA, Riezu-Boj JI, Lasarte JJ, García N, Civeira MP, et al. Viremia after one month of interferon therapy predicts treatment outcome in patients with chronic hepatitis C. Gastroenterology 1997: 113: 16471653.
  • 36
    Ampurdanés S, Olmedo E, Maluenda MD, Forns X, López-Labrador FX, Costa J, et al. Permanent response to alpha-interferon therapy in chronic hepatitis C is preceded by rapid clearance of HCV-RNA from serum. J Hepatol 1996; 827832.
  • 37
    Lee WM, Reddy KR, Tong MJ, Black M, Van Leeuwen DJ, Hollinger FB, et al. Early hepatitis C virus-RNA responses predict interferon treatment outcomes in chronic hepatitis C. HEPATOLOGY 1998; 28: 14111415.